anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Eligible subjects with NPM1 MRD positivity will receive oral arsenic trioxide (oral-As2O3) (Arsenol ®) (5-10mg per day, from days 1-7 per cycle), ascorbic acid (1g per day, from days 1 - 7 per cycle) plus azacitidine (75mg/m2 per day subcutaneously, from days 1 to 3 per cycle). Each cycle of oral-As2O3 plus azacitidine will be given once every 28 days. The total duration of treatment is 12 months (12 cycles). Treatment will be day-care and outpatient based. Reduction in the dosage and duration of oral-As2O3 is required if the subject is experiencing adverse events (AEs). In case of grade 3 or above toxicity, the dosage of oral-As2O3 will be reduced to 5mg per day. Changes or interruption in dosages, their dates and time points will be recorded on the dosage administration record and the electronic case report form (eCRF).
A described final dosage form includes a substance carrying a medicament in a first medicament-release state having a first bioavailability. The substance is modifiable ex vivo by an exposure to a first stimulus to carry the medicament in a second medicament-release state having a second bioavailability. The substance is modifiable ex vivo by an exposure to a second stimulus to carry the medicament in a third medicament-release state having a third bioavailability. The final dosage form includes another substance carrying another medicament in another first medicament-release state having another first bioavailability. The another substance is modifiable ex vivo by an exposure to another first stimulus to carry the another medicament in another second medicament-release state having another second bioavailability. The another substance is modifiable ex vivo by an exposure to another second stimulus to carry the another medicament in another third medicament-release state having another third bioavailability.
Pediatric Patients Born Small for Gestational Age (SGA) Who Fail to Manifest Catch-up Growth by Age 2

The safety and efficacy of GENOTROPIN in the treatment of pediatric patients born small for gestational age (SGA) were evaluated in 4 randomized, open-label, controlled clinical trials. Patients (age range of 2 to 8 years) were observed for 12 months before being randomized to receive either GENOTROPIN (two doses per study, most often 0.24 and 0.48 mg/kg/week) as a daily SC injection or no treatment for the first 24 months of the studies. After 24 months in the studies, all patients received GENOTROPIN.

Patients who received any dose of GENOTROPIN showed significant increases in growth during the first 24 months of study, compared with patients who received no treatment (see Table 5). Children receiving 0.48 mg/kg/week demonstrated a significant improvement in height standard deviation score (SDS) compared with children treated with 0.24 mg/kg/week. Both of these doses resulted in a slower but constant increase in growth between months 24 to 72 (data not shown).
Neonates who are hospitalized because of suspicion of NEC are subjected to intragastric microdialysis during the observation period. The catheter is placed in the stomach via the naso-oesophageal route. If surgery is necessary a microdialysis catheter is placed in the peritoneal cavity prior to wound closure. Samples are collected every 4-hour. Samples will be analyzed continuously but the results will not be included in the clinical evaluation of the patient.

A total of 20 patients will be included in this pilot study. The results of the intragastric and peritoneal microdialysis will be compared with the clinical course, s-lactate, radiological and pathological findings in each patient.
The invention discloses a blood lipid-lowering, AS (atherosclerosis)-resisting and platelet aggregation-inhibiting drug and its preparation method. The drug mainly adopts red ginseng tails, Radix Polygonum Multiflorum preparata, steamed Fructus Ligustri Lucidi, Salvia Miltiorrhiza, ligusticum wallichii, and Astragalus complanatus as raw materials, which are prepared into effective components respectively by an ''alcohol extraction method'' and an ''water extraction and alcohol precipitation method'', and then a pharmaceutically acceptable carrier or excipient is added to form the drug for oral administration. The drug and its preparation method provided in the invention are unique. The drug integrates the efficacy of blood lipid lowering, AS resisting, platelet aggregation inhibiting, fibrinolysis promoting and brain blood vessel dredging. Being able to lower blood lipid, resist AS and inhibit platelet aggregation, the drug is able to be used for blood lipid-lowering and platelet aggregation-inhibiting of the middle-aged and elderly people. Clinical experiments prove that the drug has good curative effects and has no toxic or side effect on the human body and internal organs.
Gastric polyps (GPs) are increasingly common. On upper endoscopy, they should be examined with white light and occasionally chromoendoscopy, and their morphology classified according to the Paris classification. Most GPs have a typical endoscopic appearance and can be associated with diseases like Helicobacter pylori infection. Histological examination is necessary for an accurate diagnosis. While most polyps are non-neoplastic and do not require treatment, some carry a risk of malignancy or are already malignant. Therefore, understanding the diagnosis, classification, and management of GPs is crucial for patient prognostication. Our new classification categorizes GPs into "good", "bad", and "ugly" based on their likelihood of becoming malignant. We aim to provide descriptions of the endoscopic appearance, pathology, treatment, and follow-up for different GPs, as well as clinical management flowcharts.
PURPOSE:To obtain an antilipemic agent, containing a specific benzoxazole derivative or salt thereof as an active ingredient, capable of raising high-density lipoprotein(HDL)-cholesterol value while reducing blood serum cholesterol value and useful for preventing and treating hyperlipemia and arteriosclerosis. CONSTITUTION:An antilipemic agent containing a compound expressed by formula I (R is phenyl, naphthyl, cycloalkyl or heterocyclic group optionally having a substitutent group; Alk is single direct bond, lower alkenylene, lower alkynylene or lower alkylene optionally having a substitutent group; the dotted line indicates that the bond may be double bond), e.g. 5-[(2,4-dioxothiazolidin-5-yl) methyl]-2-[4-(dimethylamino)benzyl]benzoxazole, as an active ingredient. The dose of the above-mentioned compound is 5-200mg/kg, preferably 10-20mg/kg a day. The compound expressed by formula I is novel and obtained by condensing a compound expressed by formula II (R<1> is OH, alkoxy, etc.; Y is O or NH) with a compound expressed by formula III.
BACKGROUND: Epigenetic age estimators (clocks) are predictive of human mortality risk. However, it is not yet known whether the epigenetic age of atherosclerotic plaques is predictive for the risk of cardiovascular events.
METHODS: Whole-genome DNA methylation of human carotid atherosclerotic plaques (n=485) and of blood (n=93) from the Athero-Express endarterectomy cohort was used to calculate epigenetic age acceleration (EAA). EAA was linked to clinical characteristics, plaque histology, and future cardiovascular events (n=136). We studied whole-genome DNA methylation and bulk and single-cell transcriptomics to uncover molecular mechanisms of plaque EAA. We experimentally confirmed our in silico findings using in vitro experiments in primary human coronary endothelial cells.
RESULTS: Male and female patients with severe atherosclerosis had a median chronological age of 69 years. The median epigenetic age was 65 years in females (median EAA, -2.2 [interquartile range, -4.3 to 2.2] years) and 68 years in males (median EAA, -0.3 [interquartile range, -2.9 to 3.8] years). Patients with diabetes and a high body mass index had higher plaque EAA. Increased EAA of plaque predicted future events in a 3-year follow-up in a Cox regression model (univariate hazard ratio, 1.7; P=0.0034) and adjusted multivariate model (hazard ratio, 1.56; P=0.02). Plaque EAA predicted outcome independent of blood EAA (hazard ratio, 1.3; P=0.018) and of plaque hemorrhage (hazard ratio, 1.7; P=0.02). Single-cell RNA sequencing in plaque samples from 46 patients in the same cohort revealed smooth muscle and endothelial cells as important cell types in plaque EAA. Endothelial-to-mesenchymal transition was associated with EAA, which was experimentally confirmed by TGFβ-triggered endothelial-to-mesenchymal transition inducing rapid epigenetic aging in coronary endothelial cells.
CONCLUSIONS: Plaque EAA is a strong and independent marker of poor outcome in patients with severe atherosclerosis. Plaque EAA was linked to mesenchymal endothelial and smooth muscle cells. Endothelial-to-mesenchymal transition was associated with EAA, which was experimentally validated. Epigenetic aging mechanisms may provide new targets for treatments that reduce atherosclerosis complications.
Systems, devices, and methods for delivery of a topical substance, including medicaments and/or cosmetic formulas, with carbon dioxide to the surface of the skin. The systems regulate the pH, temperature and viscosity of the topical substance, which provides benefits to the treatment of the skin. For beauty treatments, the systems lessen wrinkles of the skin and hydrate at the same time. For medicaments with active ingredients, the systems enhance delivery and ionic state using pH adjustment. The systems include devices that contain a reservoir of carbon dioxide, which flows through a heat control path where the temperature of the carbon dioxide is adjusted to a desired setting. The temperature-controlled carbon dioxide then mixes with the topical substance in a chamber, which is pressed against or applied to the skin to achieve the benefits.
BACKGROUND: Treatment of severe hemorrhagic shock typically involves hemostatic resuscitation with blood products. However, logistical constraints often hamper the wide distribution of commonly used blood products like whole blood. Shelf-stable blood products and blood substitutes are poised to be able to effectively resuscitate individuals in hemorrhagic shock when more conventional blood products are not readily available.
METHODS: Purpose-bred adult dogs (n = 6) were anesthetized, instrumented, and subjected to hemorrhagic shock (mean arterial pressure <50 mm Hg or 40% blood volume loss). Then each dog was resuscitated with one of five resuscitation products: (1) lactated ringers solution and hetastarch (LRS/Heta), (2) canine chilled whole blood (CWB), (3) fresh frozen plasma (FFP) and packed red blood cells (pRBC), (4) canine freeze-dried plasma (FDP) and hemoglobin-based oxygen carrier (HBOC), or (5) HBOC/FDP and canine lyophilized platelets (LyoPLT). Each dog was allowed to recover after the hemorrhage resuscitation event and was then subjected to another hemorrhage event and resuscitated with a different product until each dog was resuscitated with each product.
RESULTS: At the time when animals were determined to be out of shock as defined by a shock index <1, mean arterial pressure (mmHg) values (mean ± standard error) were higher for FFP/pRBC (n = 5, 83.7 ± 4.5) and FDP/HBOC+LyoPLT (n = 4, 87.8 ± 2.1) as compared with WB (n = 4, 66.0 ± 13.1). A transient increase in creatinine was seen in dogs resuscitated with HBOC and FDP. Albumin and base excess increased in dogs resuscitated with HBOC and FDP products compared with LRS/heta and CWB ( p < 0.01).
CONCLUSION: Combinations of shelf-stable blood products compared favorably to canine CWB for resolution of shock. Further research is needed to ascertain the reliability and efficacy of these shelf-stable combinations of products in other models of hemorrhage that include a component of tissue damage as well as naturally occurring trauma.
Esophageal resection remains the mainstay of treatment for esophageal cancer patients. Despite improvements in surgical technique and perioperative management, esophagectomy carries considerable operative risk. To reduce the incidence of postoperative complications and mortality of esophageal cancer, the optional of minimally invasive esophagectomy has been recommended by many guidelines since 2000s. In addition, with the development of endoscopy technology in recent years, mediastinoscopy-assisted transhiatal esophagectomy (MATHE) has been used in clinical practices. In 2015, the first mediastinoscopy combined with laparoscopic radical esophagectomy was reported systematically by Hitoshi Fujiwara. This surgical procedure has been performed in many centers of China since then. Compared with MIE, MATHE allows controlled dissection of upper mediastinum and biopsy of mediastinal lymph nodes. No study directly comparing MATHE versus MIE has been reported to date. In this report, we compare MATHE with MIE in terms of surgical feasibility, safety, and survival.We intend to adopt a randomized controlled study method. The study group is mediastinoscopy-assisted transhiatal esophagectomy (MATHE) group, and the control group is thoraco-laparoscopic esophagectomy (TLE) group. This study is expected to provide high-level evidence for the new methods and to provide better treatment options for patients with esophageal cancer.
The current small scale single-blinded randomized controlled study will build on our preliminary studies by manualizing and examining the feasibility, acceptability, and clinical effect for the Brief Intervention Medication Therapy Management (BI-MTM) model. BI-MTM is a multicomponent community pharmacy-based intervention. BI-MTM is designed to: (1) promote opioid medication regimen adherence, (2) reduce opioid medication misuse, (3) connect participants with patient navigation (a chronic condition care model) to increase self-management of health conditions that increase risk for misuse, and (4) provide naloxone rescue training referrals. Patients will be screened across 14 months for opioid medication misuse in an urban community pharmacy affiliated with a major medical system. Patients positive for misuse will be randomly assigned to BI-MTM (n=23) or Standard Medication Counseling (n=23). Standard Medication Counseling is the Centers for Medicaid and Medicare Services requirement for pharmacists in the US wherein pharmacy patients filling prescriptions receive information and opt-in counseling. This study will demonstrate feasibility and acceptability of BI-MTM for community pharmacy patients who misuse their opioid medications for future intervention implementation in a fully powered randomized trial. This study will also generate preliminary data regarding opioid medication misuse elimination and increases in participant self-management activation for comorbid health conditions that increase risk for misuse.
Hip arthroscopy has become increasingly popular in the treatment of femoroacetabular impingement syndrome. Careful preoperative planning including evaluation of acetabular and femoral version is necessary to optimize outcomes. Increased femoral anteversion has been associated with microinstability, and conversely, decreased femoral version may predispose to impingement. Computed tomography (CT) is considered the gold standard for femoral version measurements and preoperative planning. However, with recent advancements in technology, magnetic resonance imaging (MRI) has shown comparable measurements to CT imaging. In terms of advantages and disadvantages, CT requires radiation, albeit "low dose." MRI has a longer acquisition time, and movement of the patient may affect image quality and subsequent accuracy. MRI generally underestimates true version, probably as a result of patient positioning. Three-dimensional imaging could resolve this issue and may become the gold standard for both CT and MRI.
PROBLEM TO BE SOLVED: To obtain a dermal preparation for external use, having excellent inhibiting actions on the tyrosinase activities and promoting actions on the production of collagen, effective in lightening the color and beautifying and whitening of pigmentation, dermal stains, ephelides, chloasma, etc., after sunburn and capable of preventing the skin from aging. SOLUTION: This dermal preparation for external use comprises an extract of a plant belonging to the genus Elephamtopus of the family Compositae [e.g. Tapak limam (botanical name: Elephamtopus scaber L.)] as an active ingredient in an amount of 0.0005-20wt.%, preferably 0.001-10wt. expressed in terms of a dried substance therein. The Tapak limam is the plant growing in especially a dry grassland, a pasture, etc., of Indonesia and the extract is obtained by immersing the whole herb together with an organic solvent such as ethanol therein or refluxing the mixture under heating, then filtering and concentrating the resultant filtrate. Usually used ingredients can further suitably be blended therewith to prepare an ointment, a cream, a milky lotion, a lotion, a pack, a bathing agent, etc.  Thereby, the elastic skin without any wrinkles or slacks can be retained to maintain the state of the fresh skin.
A method for screening of modulators of calcineurin is provided, which uses the interaction between calcineurin and superoxide dismutase. Modulators of calcineurin are potential candidates for drugs, e.g. for immunesuppressive drugs. The forming of a complex comprising calcineurin and superoxide dismutase is monitorable in the presence of potential activators or inhibitors of calcineurin. Complex formation is performed within the cell by the use of appropriate expression vectors or in vitro using isolated proteins.  Preferably, complex formation is monitored by fluorescence detection, especially by laser fluctuation correlation spectroscopy.
<P>PROBLEM TO BE SOLVED: To determine a radiologist in charge of a medical image in a real time according to the schedule of the radiologist.  <P>SOLUTION: When the log-in of a radiologist is operated by any diagnosing terminal 40, a server 20 sets a flag showing that the radiologist has logged-in in a log-in table. Then, when a new medical image is inputted from a modality 10, the image type of the medical image is discriminated, and the radiologist in charge set as a doctor in charge of diagnostic reading is discriminated at the current date corresponding to the type of an image based on a schedule table. Furthermore, whether or not the radiologist in charge has logged-in is discriminated based on the log-in table in the high priority order set in the schedule table, and the radiologist in charge who has logged-in is permitted to access to the medical image. The medial image whose access has been permitted is added to the list of medial images being the object of diagnostic reading by the diagnosing terminal 40.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
All enrolled patients will receive a test dose of talimogene laherparepvec (10\^6 plaque forming units (PFU)/ml) on day 1, followed by treatment doses at escalating concentrations weeks 4, 7, and 10. A biopsy will be obtained during each scheduled endoscopy prior to talimogene laherparepvec injection.
For ECT, the pulse width of the electrical stimulus was set to 0.5 ms. The initial energy dosage was determined based on the patient's age, with subsequent sessions increasing by 5% increments. In cases of inadequate seizure duration (\<25 s), the maximum dosage was administered in the following session. If no seizures were induced, the maximum dosage was administered immediately.
Changes to blood-brain barrier structure and function may affect the delivery of drugs into the brain. It is worthwhile to exploring more study on how the blood-brain barrier changes in structure and function and how that affects drug transport in high-altitude hypoxic environment. The DIA high-throughput sequencing technique indicate that the rats blood-brain barrier has been identified to have 7252 proteins overall and 8 tight junction proteins, among which Claudin-7 was a plateau-specific tight junction protein under high-altitude hypoxia, and based on the interaction network study, 2421 proteins are found to interact with one another, with ZO-1 being the primary target. The results of the projected gene function analysis demonstrated that changes in tight junction proteins are related to the control of TRP channels by inflammatory mediators, the wnt signaling pathway, the ABC transporter system, and drug metabolism-CYP450 enzyme regulation. Additionally, the electron microscopy, the Evans blue combination with confocal laser scanning microscopy, and the Western Blot and RT-qPCR revealed that high-altitude hypoxic environment induces blood-brain barrier tight junctions to open, blood-brain barrier permeability increases, ZO-1, Occludin, Claudin-5 protein and mRNA expression decreased. Our research implies that structural and functional alterations in the blood-brain barrier induced by high altitude hypoxia may impact drug transport inside the central nervous system, and that drug transporters and drug-metabolizing enzymes may be key players in this process.
Benign hepatic adenomas are associated with oral contraceptive use, although the incidence of benign tumors is rare in the United States. Indirect calculations have estimated the attributable risk to be in the range of 3.3 cases/100,000 for users, a risk that increases after four or more years of use especially with oral contraceptives of higher dose (49). Rupture of rare, benign, hepatic adenomas may cause death through intra-abdominal hemorrhage (50, 51).

Studies from Britain have shown an increased risk of developing hepatocellular carcinoma (43-45) in long-term (> 8 years) oral contraceptive users. However, these cancers are extremely rare in the US and the attributable risk (the excess incidence) of liver cancers in oral contraceptive users approaches less than one per million users.

###  5\. Risk of Liver Enzyme Elevations with Concomitant Hepatitis C Treatment

During clinical trials with the Hepatitis C combination drug regimen that contains ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, ALT elevations greater than 5 times the upper limit of normal (ULN), including some cases greater than 20 times the ULN, were significantly more frequent in women using ethinyl estradiol-containing medications such as COCs. Discontinue VIORELE® prior to starting therapy with the combination drug regimen ombitasvir/paritaprevir/ritonavir, with or without dasabuvir [see CONTRAINDICATIONS]. VIORELE® can be restarted approximately 2 weeks following completion of treatment with the combination drug regimen.
PURPOSE:To obtain a treating agent for upper respiratory inflammation such as throat ache and laryngeal ache occurring in cold, etc., comprising allopurinol as an active ingredient. CONSTITUTION:Allopurinol and carboxymethyl cellulose are ground, blended, stirred with sterilized pure water and adjusted to proper concentration to give the objective substance. 1 pt.wt. allopurinol is used with 5-50 pts.wt. carboxymethyl cellulose or water-soluble salt thereof and 100-2,000 pts.wt. water to prepare the objective substance. The allopurinol solution is diluted with water by a factor of several to tens times and one's throat is gargled with the solution in a proper concentration about twice to 10 times daily.